miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24087215 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Xiaohui Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, MicroRNAs, Extracellular Vesicles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institute of General Medical Sciences of the National Institutes of Health.
Abstract (Originalsprache)
Pancreatic cancer is the third leading cause of cancer-related death in the United States. Pancreatic ductal adenocarcinoma (PDAC) is the major form of pancreatic cancer with the worst outcomes. Early detection is key to improving the overall survival rate of PDAC patients. Recent studies have demonstrated that microRNA (miRNA) signatures in plasma small extracellular vesicles (EVs) are potential biomarkers for the early detection of PDAC. However, published results are inconsistent due to the heterogeneity of plasma small EVs and the methods used for small EV isolation. We have recently refined the process of plasma small EV isolation using double filtration and ultracentrifugation. In the present study, we applied this protocol and analyzed plasma small EV miRNA signatures by small RNA sequencing and quantitative RT-PCR in a pilot cohort, consisting of patients with early-stage PDAC, and age- and gender-matched healthy subjects (n = 20). We found, via small RNA sequencing, that there are several miRNAs enriched in plasma small EVs of PDAC patients, and the levels of miR-18a and miR-106a were confirmed by quantitative RT-PCR to be significantly elevated in patients with early-stage PDAC compared with age- and gender-matched healthy subjects. Furthermore, using an immunoaffinity-based plasma small EV isolation approach, we confirmed that the levels of miR-18a and miR-106a in plasma small EVs were significantly higher in PDAC patients versus the healthy subjects. We thus conclude that the levels of miR-18a and miR-106a in plasma small EVs are promising biomarkers for the early detection of PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
- Department of Biostatistics & Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
- Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126, USA.
ORCID-Profile: Kritisha Bhandari, Chao Xu, Katherine Morris, Wei-Qun Ding
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Institute of General Medical Sciences of the National Institutes of Health
- National Cancer Institute Cancer Center
- Presbyterian Health Foundation
Zitieren
APA
Xu, X., Bhandari, K., Xu, C., Morris, K., & Ding, W. Q. (2023). miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24087215
Vancouver
Xu X, Bhandari K, Xu C, Morris K, Ding WQ. miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24087215
BibTeX
@article{Xu2023,
author = {Xu, Xiaohui and Bhandari, Kritisha and Xu, Chao and Morris, Katherine and Ding, Wei-Qun},
title = {miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24087215}
}
EUVIMED